Advertisement
UK markets closed

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

  • HANG SENG

    17,201.27
    +372.34 (+2.21%)
     

  • CRUDE OIL

    82.89
    -0.47 (-0.56%)
     

  • GOLD FUTURES

    2,331.10
    -11.00 (-0.47%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • Bitcoin GBP

    51,312.13
    -1,814.77 (-3.42%)
     

  • CMC Crypto 200

    1,385.77
    -38.33 (-2.69%)
     

  • NASDAQ Composite

    15,712.75
    +16.11 (+0.10%)
     

  • UK FTSE All Share

    4,374.06
    -4.69 (-0.11%)
     
Money:

The five essential pieces of financial paperwork you must never lose

Mislaying key documents can cause real headaches, so it’s worth tracking down these most commonly-lost bits of paperwork

Galapagos, GSK successfully conclude phase 2a study of skin disease drug

Reuters - UK Focus

BRUSSELS, April 17 (Reuters) - Belgian biotech group Galapagos NV (Other OTC: GLPGF - news) on Thursday said it has successfully concluded the phase 2a study of a skin disease drug it is developing with Britain's GlaxoSmithKline PLC (Other OTC: GLAXF - news) .

Galapagos tested drug GSK2586184 on 66 patients with chronic psoriasis and observed a 75 percent improvement in significantly more patients than in the placebo group.

GSK, which owns the drug's commercial rights, will decide whether to proceed with clinical trials, Galapagos said in a statement.

Galapagos said it could receive a milestone payment of up to 34 million euros ($46.94 million) as well as double-digit royalties as the programme proceeds towards commercialisation.

($1 = 0.7243 Euros) (Reporting by Robert-Jan Bartunek; Editing by Christopher Cushing)